Evaxion A/S (EVAX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Evaxion A/S (EVAX) closed at USD 2.80 on 2026-10-14, a change of -56.8 % over the past year, with a market capitalization of USD 25.26M.

Evaxion A/S recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Evaxion A/S key figures

Previous close

USD 2.80 (2026-10-14)

1-year change

-56.8 %

Market cap

USD 25.26M

Enterprise value

USD 16.46M

P/E ratio (trailing)

-2.72

P/E ratio (forward)

-186.67

EPS (trailing)

-1.03

EPS (forward)

-0.02

PEG ratio

n/a

Price to book

2.45

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.06

Employees

46

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Evaxion A/S

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Evaxion A/S and compare it with other stocks.